New hope for arthritis sufferers: experimental drug shows promise in Late-Stage trial

This study tests a new oral drug called LNK01001 (Zemprocitinib) in 430 adults with moderate-to-severe rheumatoid arthritis who have not improved with other biologic treatments. Participants receive either the drug or a placebo for 24 weeks, followed by a long-term safety extension. The goal is to reduce joint pain, swelling, and inflammation, but ongoing medication is still needed.